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Abstract
A critical problem in biology is understanding how cells choose between self-renewal and differentiation. To generate a
comprehensive view of the mechanisms controlling early hematopoietic precursor self-renewal and differentiation, we used
systems-based approaches and murine EML multipotential hematopoietic precursor cells as a primary model. EML cells give
rise to a mixture of self-renewing Lin-SCA+CD34+ cells and partially differentiated non-renewing Lin-SCA-CD342 cells in a
cell autonomous fashion. We identified and validated the HMG box protein TCF7 as a regulator in this self-renewal/
differentiation switch that operates in the absence of autocrine Wnt signaling. We found that Tcf7 is the most down-
regulated transcription factor when CD34+ cells switch into CD342 cells, using RNA–Seq. We subsequently identified the
target genes bound by TCF7, using ChIP–Seq. We show that TCF7 and RUNX1 (AML1) bind to each other’s promoter regions
and that TCF7 is necessary for the production of the short isoforms, but not the long isoforms of RUNX1, suggesting that
TCF7 and the short isoforms of RUNX1 function coordinately in regulation. Tcf7 knock-down experiments and Gene Set
Enrichment Analyses suggest that TCF7 plays a dual role in promoting the expression of genes characteristic of self-
renewing CD34+ cells while repressing genes activated in partially differentiated CD342 state. Finally a network of up-
regulated transcription factors of CD34+ cells was constructed. Factors that control hematopoietic stem cell (HSC)
establishment and development, cell growth, and multipotency were identified. These studies in EML cells demonstrate
fundamental cell-intrinsic properties of the switch between self-renewal and differentiation, and yield valuable insights for
manipulating HSCs and other differentiating systems.
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Introduction
Stem cells are characterized by the ability to both self renew and
undergo cell differentiation. Understanding the mechanisms that
control the switch between renewal and differentiation is a
fundamental and important problem in stem cell biology. It is
likely that many key components including signaling molecules
and transcription factors are involved in this process. Although a
few key components that influence the switch have been found
[1,2,3,4], it likely that many others exist. Identification of such
components and elucidation of how they function is critical for
understanding this developmental switch.
Blood-forming hematopoietic stem cells (HSCs) are one of the
best-characterized stem cells, and are valuable for studying self
renewal and differentiation [5,6]. HSCs exist in adult bone
marrow, and can self-renew and differentiate into more than ten
distinct mature blood cell lineages after transplantation in vivo [7].
Understanding the mechanisms that regulate differentiation of
HSCs into the different cell types is expect to be important for
understanding hematopoietic diseases and manipulating HSCs for
therapeutic purpose. However, because HSCs are currently
unable to proliferate extensively in vitro without losing their
‘‘stemness’’, large cultures cannot be produced [8]. This severely
limits the types of biochemical and genomic analyses that can be
PLoS Genetics | www.plosgenetics.org 1 March 2012 | Volume 8 | Issue 3 | e1002565performed, and consequently, the mechanisms that control the
decision between early-stage HSC self-renewal and differentiation
remain unclear.
The mouse (Mus musculus) EML (Erythroid, Myeloid, and
Lymphocytic) multipotential hematopoietic precursor cell is an
ideal system for studying the molecular control of early
hematopoietic differentiation events. EML cells are derived from
mouse bone marrow cells that have been transfected with a
retrovirus expressing a dominant negative retinoic acid receptor
and were subsequently cultured in the presence of stem cell factor
(SCF). These cells can be re-derived or repeatedly cloned and still
retain their multipotentiality [9,10,11]. The ability of EML cells to
propagate extensively in medium containing SCF makes them
ideal for biochemical and genetic assays as well as high throughput
functional screens [7,12]. Phenotypically, EML cells express many
of the cell surface markers characteristic of hematopoietic
progenitor cells, including SCA1, CD34, and c-KIT. Functionally,
when treated with different growth factors, such as SCF, IL-3,
GM-CSF, and EPO, EML cells can differentiate into distinct cell
lineages including B-lymphocyte, erythrocyte, neutrophil, macro-
phage, mast cell, and megakaryocyte lineages [9]. Unlike
maturation of human promyelocytic cell lines, such as NB4 and
HL60, EML cell derivatives develop into mature neutrophils with
segmented nuclei and azurophilic granules [9]. Thus, EML cells
are biologically relevant for normal hematopoiesis.
Interestingly, in culture the Lin-SCA+CD34+ subpopulation of
EML cells, which can be isolated by magnetic-activated cell
sorting (MACS) beads or Fluorescence Activated Cell Sorting
(FACS), gives rise in culture to a mixed population containing
similar numbers of self renewing Lin-SCA+CD34+ precursor cells
and partially differentiated Lin-SCA-CD342 cells (henceforth
referred to as CD34+ and CD342 cells, respectively) [13].
Although the two populations resemble each other morphologi-
cally, only the CD34+ population propagates in SCF-containing
media, while the CD342 cells do not self-renew in SCF; instead,
their growth requires the cytokine IL-3 [13]. The closest normal
analogs of CD34+ cells are short-term (ST)-HSC or multipotent
progenitors (MPP). Similar to short-term (ST)-HSC, CD34+ cells
are capable of self-renewal; like MPP, when treated with cytokines
such as IL-3, CD34+ cells can give rise to CD342 cells with more
restricted potential. A number of erythroid genes, such as a- and
b-hemoglobin, Gata1, Epor (erythropoietin receptor), and Eraf
(erythroid associated factor), as well as mast cell proteases are
expressed at a significantly higher level in the CD342 cell
population than CD34+ cells [13,14]. This indicates that the
CD342 cells were, at minimum, differentiated into a state with
prominent erythroid potential.
The ability of CD34+ cells to both differentiate and self-renew
in suspension culture in the absence of any anatomical niche or
other cell type suggests that CD34+ cells are regulated by a tightly
controlled endogenous mechanism that guides the generation of
the variety and relative abundance of the cell types in culture.
Understanding the molecular events that regulate the transition
between the two types of putative precursors in the EML
multipotent hematopoietic cell line will give insights to the
fundamental mechanisms of autonomous balanced selection of
alternative cell fates available for stem cells and intermediate-stage
cancer precursor cells [7].
What is the mechanism that regulates the decision between the
two types of precursor cells? One possible mechanism is by
modulating the levels of key transcriptional regulators. This
hypothesis is suggested by the findings that Pu.1 or Gata1 play a
determining role in downstream hematopoietic lineage decisions
[15,16]. Higher Pu.1 expression switches the differentiation to the
myeloid lineages [16,17] whereas Gata1 shifts cells towards the
erythroid lineage. In light of this, we examined transcription
factors that were significantly up-regulated in CD34+ cells
relative to CD342 cells using RNA sequencing (RNA-Seq) and
found Tcf7 (also referred to by the symbol Tcf1) to be the most
strongly up-regulated transcription factor. TCF7 is a member of a
family of HMG box containing factors that are known to
associate with beta-catenin in the nucleus to mediate Wnt
signaling [18,19,20]. Wnt signaling has been implicated in
hematopoietic stem cell and precursor maintenance and affects
the decision between self-renewal and differentiation [21,22,23,
24] although its role in EML cells is not yet defined. It has been
reported that TCF7 plays a role in B cell and T cell development
and is a possible co-regulator in mouse embryonic stem cells, but
TCF7 has not been noted for its function in earlier decisions in
hematopoietic development [25,26]. The binding motifs of the
TCF family of transcription factors are significantly enriched
among genes that are expressed at a higher level in CD34+ than
in CD342 cells. Therefore, we hypothesized that TCF7 is one of
the key transcription factors that control a transcriptional
regulatory network determining the choice between EML cell
self-renewal and differentiation.
We identified in vivo binding targets of TCF7 using ChIP-Seq
(chromatin immunoprecipitation in combination with high-
throughput sequencing). We found TCF7 binds to its own
promoter and the promoter of Runx1 (Aml1), a developmental
determinant in hematopoietic cells that is best known for its critical
role in hematological malignancies [27,28]. RUNX1 and TCF7
were found to bind to each other’s promoters and a large number
of common target genes are bound by RUNX1 and TCF7.
Analysis correlating gene expression and transcription factor
binding data suggests that TCF7 is necessary to maintain cells in
the undifferentiated state. We validated this hypothesis by knock-
down of Tcf7 expression. Finally, through network analysis, we
found that TCF7 and RUNX1 bind and regulate a network of up-
regulated transcription factors in the CD34+ cells which
characterize the self-renewal property of the CD34+ cells.
Author Summary
The hematopoietic system has provided a leading model
for stem cell studies, and there is great interest in
elucidating the mechanisms that control the decision of
HSC self-renewal and differentiation. This switch is
important for understanding hematopoietic diseases and
manipulating HSCs for therapeutic purposes. However,
because HSCs are currently unable to proliferate exten-
sively in vitro, this severely limits the types of biochemical
analyses that can be performed; and, consequently, the
mechanisms that control the decision between early-stage
HSC self-renewal and differentiation remain unclear.
Murine bone marrow derived EML multipotential hemato-
poietic precursor cells are ideal for studying the switch.
EML cells can grow in large culture and give rise to a
mixture of self-renewing Lin-SCA+CD34+ cells and partially
differentiated non-renewing Lin-SCA-CD342 cells in a cell
autonomous fashion. Using RNA–Sequencing and ChIP–
Sequencing, we identified and validated the HMG box
protein TCF7 as a regulator in this switch and find that it
operates in the absence of canonical Wnt signaling.
Together with RUNX1, TCF7 regulates a network of
transcription factors that characterize the CD34+ cell state.
This work serves as a model for studying mechanisms of
autonomous and balanced cell fate choice and is
ultimately valuable for manipulating HSCs.
TCF7, a Key Regulator of Self-Renewal in EML Cells
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autocrine Wnt signaling. Our results thus elucidate novel
components and mechanisms that control stem cells renewal and
differentiation.
Results
Differentially expressed genes in CD34+ and CD342 EML
precursor cells identified using RNA–Seq
Global identification of gene expression can provide significant
insight into molecules important for the self-renewal and
differentiation decisions in EML cells. Differential gene expression
between CD34+ and CD342 cells was first studied using cDNA
microarrays [13]. As cDNA microarrays do not cover the entire
transcriptome, we decide to investigate the gene expression profiles
of CD34+ and CD342 cells using the RNA-Seq technology. We
generated 35 nt single end and long 75 nt paired-end reads
(sequence reads from both ends of cDNA fragments) using
Illumina technology. Although the overall patterns of mRNA
levels are similar in CD34+ and CD342 cells, the expression levels
of a limited number of transcription factors differ in the two cell
populations (Figure 1; Dataset S1).) Notably, the expression level
of Tcf7 was found to be over 100 fold higher in the CD34+ cells
relative to CD342 cells, where it is very low. In fact Tcf7 is as
strongly regulated as the cell surface marker Cd34 itself.
Tcf7 is a member of the T-cell factor family including Tcf3,a n
essential component of the core regulatory network controlling the
balance between pluripotency and differentiation in mouse
embryonic stem (mES) cells [29]. However, the Tcf3 expression
level is very low in EML cells, and neither Tcf3 nor other TCF
family members displayed the remarkable differential gene
expression observed for Tcf7. Other interesting transcription
factors that we found to be up-regulated in CD34+ cells include:
Sox4, Jun, Stat3, Smad1, Cebpa, Bcl6, Bcl3, Bcl9, Fos, Runx1 and Cbfb
(Figure 1). Consistent with the microarray study, we also found
that transcription factors involved in erythroid differentiation, such
as Gata1, Gfi1b Klf1 and Klf3, are up-regulated in CD342 cells
(Figure 1).
Enriched functional categories and motif analysis of
differentially expressed genes
We next examined the functional categories of differentially
expressed transcription factors in either CD34+ or CD342 cells
using Ingenuity Pathway Analysis software (IPA). The top three
significant categories in Molecular and Cellular Functions are
‘‘Gene Expression’’, ‘‘Cellular Development’’, and ‘‘Cellular
Growth and Proliferation’’, whereas the top three significant
categories in Physiological System Development and Function are:
‘‘Hematological System Development and Function’’, ‘‘Hemato-
poiesis’’, and ‘‘Tissue Morphology’’ (Table S1). These categories
are consistent with the suggestion that the switch from CD34+ to
CD342 cells represents a developmental process towards a less
proliferative and more differentiated state.
To further identify the potential transcription factors that
control the group of genes up-regulated in CD34+ cells, we
performed Distant Regulatory Elements analysis (DiRE http://
dire.dcode.org/). DIRE analyzes not only the proximal promoter
regions but also the full gene locus including intergenic, promoter,
intronic and UTR (upstream untranscribed regions). Among the
DNA sequence motifs that were enriched in up-regulated genes
(.1.5 fold) in CD34+ cell in comparison to CD342 cells, were
binding motifs for members of the TCF family of transcription
factors (Figure S1).
Analysis of gene expression of Wnt pathway components
showed minimum endogenous Wnt signaling in EML
cells
TCF7 has previously been studied as a partner with nuclear
beta-catenin, which serves as a downstream transcriptional
activator in response to external Wnt signaling. TCF7 potentially
acts as a transcriptional repressor in the absence of beta-catenin
[18,19]. We therefore examined the data for expression of
components of the Wnt signaling pathway. Internal components
of the pathway such as Apc, Axin1, Bcl9, Daam1, Gsk3a and Gsk3b
were expressed at the mRNA level (Table S2) in both CD34+ and
CD342 cells. Activation of the canonical Wnt pathway is achieved
primarily through various Wnt ligands binding to LRP5/6 and/or
frizzled (FZD) receptors. Of the components of canonical Wnt
receptors, a moderate level of Lrp5/6, Fzd2 and Fzd7 mRNA were
detected by either RNA-Seq or Illumina microarrays analysis, and
even lower levels of mRNA for other Frizzled genes. Based on
RNA-Seq data, the Wnt ligands were absent with the exception of
Wnt9a and Wnt10a which were present in trace amounts (Table
S2). The Illumina microarray also reported the presence of low
levels of Wnt10a mRNA. To further test for the presence of
Wnt10a mRNA, four sets of PCR primers were designed that
crossed introns, and could distinguish between genomic DNA and
spliced cDNA. Each set of primers gave the anticipated band from
mouse embryonic fibroblast cDNA, but none showed any band of
the specific product using CD34+ cell cDNA (data not shown).
Despite the fact Tcf7 expression is abundant; the absence or
very low level of mRNA for Wnt ligands suggests that EML cells
have little or no endogenous Wnt signaling. To test this possibility
we utilized a Tcf/Lef GFP reporter to monitor Wnt activity in
EML cells. The Tcf/Lef reporter is under the control of a
minimum CMV promoter fused in tandem to Tcf/Lef transcrip-
tional response elements. EML cells containing the positive control
CMV-GFP construct showed uniform robust expression in EML
cells (Figure S2). By contrast, cells containing the Tcf/Lef reporter
failed to express GFP. To circumvent the possibility that the Tcf/
Lef reporter is non functional in EML cells, we incubated the cells
with either LiCl (50 mM), Wnt3a or Wnt5a (400 uM) for
24 hours. LiCl, a GSK3beta-inhibitor, has been previously used
to activate the Wnt pathway [30,31]. Upon stimulation with LiCl
we noted a significant increase in GFP expression (52 fold
enrichment when MOI=5; 85 fold enrichment when MOI=10)
suggesting that cells are capable of receiving and activating the
Tcf/Lef reporter (Figure S2). Tcf/Lef reporter activation using Wnt
ligands was also observed, although it was lower than LiCl
activation (data not shown) consistent with the findings that EML
cells have low levels of frizzled receptors. These data demonstrate
that while the cells are capable of response to activation of the
internal Wnt response system, there is no endogenous Wnt
signaling in EML cells detectable with the commonly used Wnt
reporter system.
Identification of TCF7 in vivo binding targets
In order to better understand how TCF7 may be involved in the
switch from self-renewing CD34+ cells to partially differentiated
CD342 cells, we identified the in vivo binding sites for TCF7 using
ChIP-Seq [32,33]. We also performed PolII ChIP-Seq to follow
genes that were activated or poised for activation. ChIP-Seq
experiments identified 9696 TCF7 binding sites with a q-value
(Benjamini Hochberg corrected p-value),=0.001 (Dataset S2).
The binding sites were mapped to RefSeq genes in the UCSC
mm9 database (genome.ucsc.edu). The binding sites were assigned
to a particular gene if the peak was present within 3 kb upstream
TCF7, a Key Regulator of Self-Renewal in EML Cells
PLoS Genetics | www.plosgenetics.org 3 March 2012 | Volume 8 | Issue 3 | e1002565Figure 1. Heatmap display of transcription factors that differential expressed (.1.5 fold) between Lin-CD34+ cell and Lin-CD342
cells. Two replicas were shown for each cell type. Red color represents up-regulated genes and green color represents down-regulated genes. Genes
mentioned in the text are labeled. Cd34 and Ly6a (Sca1) are cell surface markers. See ‘‘Methods’’ for the calculation of Z scores.
doi:10.1371/journal.pgen.1002565.g001
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exonic and intronic regions)(Dataset S4). ,85% of TCF7 binding
peaks were assigned to known genes using this approach. These
sites were mapped to 7976 TCF7 target genes. Among the
interesting binding sites was the presence of TCF7 at its own
promoter region in CD34+ cells (Figure 2A), raising the possibility
that TCF7 regulates its own transcription through an autoregu-
latory feedback loop. qPCR experiments verified the enrichment
of TCF7 binding at the Tcf7 promoter region in CD34+ cells using
TCF7 antibody compared to IgG immunoprecipitation.
To explore the biological processes that are regulated by TCF7,
the functional categories associated with TCF7 target genes were
examined based on annotations in the Gene Ontology (GO)
database [34]. Enriched GO categories were identified and
displayed using the BiNGO program (http://www.psb.ugent.be/
cbd/papers/BiNGO/) (Figure S3) [35]. Genes associated with
regulation of transcription were highly enriched in TCF7 targets,
consistent with our hypothesis that TCF7 functions as a key
transcription regulator in the decision of EML cell self-renewal
and differentiation. Other significantly enriched functional
categories include cell development and differentiation, metabolic
processes, and signaling.
RUNX1 functions coordinately with TCF7 in regulating
target genes
In an effort to understand how the expression of Tcf7 itself is
controlled to regulate hematopoietic development, we examined
the promoter of Tcf7 for other potential regulators. Evolutionarily
conserved RUNX1 (AML1) binding sites were identified at the
Tcf7 promoter region (Figure 2B) using the software REGULA-
TORY VISTA (http://ecrbrowser.dcode.org). In addition, the
Runx1 expression pattern is consistent with Tcf7 regulation, i.e.
although expressed in both CD34+ and CD342 cells, Runx1
mRNA is up-regulated 3.7 fold in the CD34+ cells as shown by
RNA-Seq data (Figure 1). Using a previously validated anti-
RUNX1 rabbit polyclonal antibody [36], ChIP-Seq experiments
identified 21932 RUNX1 binding sites with a q-value (Benjamini
Hochberg corrected p-value),=0.001 (Dataset S3). These sites
were mapped to 5393 RUNX1 target genes (Dataset S4). We
performed de novo binding motif search among sequences bound
in TCF7 and RUNX1 ChIP-Seq experiments, and found they
overlap well with the known motifs (from Jaspar and Transfac
databases) of RUNX1 and TCF7 (Figure S4). We found RUNX1
binds to the Tcf7 promoter (Figure 2A), as well as its own
promoter. Therefore, it is likely that autoregulation of RUNX1
contributes to the regulation of Tcf7. Furthermore, TCF7 also
binds to the Runx1 gene (Figure 2C). Since both transcription
factors bind to their own respective promoters as well as to each
other, one intriguing possibility is that TCF7 and RUNX1 may
co-regulate each other in a feed-back loop.
We used three approaches to test whether RUNX1 functions
coordinately with TCF7 in regulating target genes. In the first
approach we compared the TCF7 ChIP-Seq and RUNX1 ChIP-
Seq data to identify the overlapping set of target genes for the two
transcription factors. Among 7976 TCF7 target genes (Figure 3A,
blue circle in the Venn diagram) and 5393 RUNX1 target genes
(Figure 3A, red circle), 3915 target genes are in common (72% of
all RUNX1 targets and 49% of all TCF7 target genes are
common; see Figure 3A). The hypergeometric p-value of the
intersection is 6.72294e-56. Thereby, TCF7 and RUNX1 binding
target lists showed a statistically significant overlap. In the second
approach, the proximity of RUNX1 and TCF7 binding peaks
were analyzed. The distance of the nearest RUNX1 peak to each
of the TCF7 peak was identified. RUNX1 peaks either overlap
with, or are within 500 nt upstream or downstream of 4691 of the
9696 TCF7 peaks (48%; Figure 3B). The third approach used
motifs to which the factors are known to bind. Two versions of the
known motifs for TCF7 and two known motifs for RUNX1 were
obtained from Jaspar and Transfac databases. We assessed the
occurrence of each of these motifs within the experimentally
identified binding sites of TCF7 and RUNX1. Within TCF7
peaks, at least 44% of the peaks contained one version of the
TCF7 motif and 54% of the peaks contained at least one RUNX1
motif. Within the RUNX1 peaks, 46% had a TCF7 motif and
78% had a RUNX1 motif (Figure 3C). Based on all above-
mentioned analyses, we conclude TCF7 and RUNX1 bind to a
large number of shared target genes and likely function
coordinately in regulation of gene expression.
TCF7 primarily binds to the genes up-regulated in CD34+
cells
To determine how the differential gene expression in CD34+
and CD342 cells is related to TCF7 regulation, Gene Set
Enrichment Analysis (GSEA) [37] was performed to correlate
transcription factor binding information with the gene expression
data. The GSEA software is designed to determine whether
members of a gene set, for example TCF7 binding targets, are
randomly distributed throughout the gene expression data or
primarily enriched among genes most highly up or down-regulated
during the switch from CD34+ to CD342 cells. The expression
dataset was rank-ordered by fold change such that the most up-
regulated genes in CD34+ cells were at the top of the ranked list,
while most up-regulated genes in CD342 cells (down-regulated
genes in CD34+ cells) were at the bottom of the ranked list. GSEA
analysis showed a statistically significant enrichment (P near 0) of
TCF7 targets among up-regulated genes in CD34+ cells, in
comparison to the distribution expected at random (Figure 4A).
Overall, these observations strongly indicate that TCF7 primarily
binds to genes up-regulated in CD34+ cells. A similar enrichment
was observed for RUNX1 binding targets (Figure 4B) so that both
of these factors predominantly bind to genes up-regulated in
CD34+ cells.
Tcf7 shRNA gene inhibition confirms that Tcf7 is
necessary to maintain cells in the undifferentiated state
To further understand how Tcf7 affects CD34+ cell self renewal
or differentiation, we used shRNA constructs targeting different
regions of the Tcf7 gene. Three Tcf7 shRNA constructs caused
significant reduction in levels (36–54%) of gene expression as
confirmed by qRT-PCR experiments and Western blots
(Figure 5A, 5B), and we observed obvious effects from the
knockdown experiments. Consistent with the hypothesis that
Runx1 and Tcf7 act coordinately, knockdown of Tcf7 caused the
short isoforms of RUNX1 to disappear at the protein level,
without changing the expression of the long isoform (Figure 5B).
Illumina bead microarray analysis of cells with reduced expression
using one of the constructs revealed that 1510 genes changed .1.5
fold in Tcf7 knockdown lines compared to a scrambled shRNA
negative control line (711 down-regulated and 799 up-regulated
genes)(Microarray data is available in the Gene Expression
Omnibus (GEO) microarray data repository; record GSE30068).
Gene Set Enrichment Analysis (GSEA) was performed to correlate
these differentially expressed genes in Tcf7 knockdown lines with
the differential gene expression between CD34+ and CD342 cells.
We found that the down-regulated genes in Tcf7 shRNA
knockdown cells are significantly enriched among up-regulated
genes in CD34+ cells (Figure 5C; P near 0). On the other hand, the
TCF7, a Key Regulator of Self-Renewal in EML Cells
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cantly enriched among up-regulated genes in CD342 cells
(Figure 5D; P near 0). Therefore, the gene expression profile of
Tcf7 knockdown cells shifted toward a partially differentiated
CD342 state. Overall these results suggest that Tcf7 is necessary
for maintaining cells in the undifferentiated CD34+ state but is
also necessary for switching to the partially differentiated CD342
state.
TCF7 and RUNX1 regulate a transcriptional regulatory
network that is involved in hematopoietic stem cell
establishment and development, cell growth control,
and multipotency
To understand the intricate relationship of the transcription
regulators defining the state of CD34+ cells, we employed
Ingenuity Pathway Analysis software (IPA) to identify a network
among up-regulated transcription factors in CD34+ cells (.2
fold) (Figure 6). TCF7 and RUNX1 and many transcription
factors bound by TCF7 or RUNX1 are found in this network.
Overall, three main functional groups can be identified: 1). HSC
establishment and development during early hematopoiesis
(marked in red in Figure 6). This group includes Sox4, Fos,
Tal1 and Etv6. Fos and Sox4 were identified as novel nuclear
factors that affect hematopoietic stem cell activity. Overexpres-
sion of Fos and Sox4 induced enhanced HSC activity and
resulted in an increased repopulating activity compared to the
untreated cells [38]. Tal1/Scl is required during the establish-
ment of primitive and definitive haematopoiesis, and plays a
role in erythromyeloid lineage commitment [39,40]. Etv6/Tel is
shown to regulate postembryonic HSC survival and is essential
for multilineage haematopoiesis in the bone marrow (Hock et al.
2004). CBFB (core-binding factor, beta subunit) is the binding
partner of RUNX1. 2). Cell growth control (marked in blue in
Figure 6). This group includes Stats, Ppard, Erg and the Tgfb
signaling pathway components Smads etc. 3). Multipotency
(marked in yellow in Figure 6). The multipotency of CD34+
cells is reflected in genes involved in lineage specification. For
example, Cebpa is a regulator of myelomonocytic lineage
commitment. Gfi1 promotes GMP (common myeloid progen-
itor) differentiation towards the neutrophilic lineage [40]. ETS
transcription factor FLI-1 interacts with RUNX1-containing
multiprotein complexes through protein-protein interactions
and is involved in the transcriptional regulation of megakaryo-
cyte maturation (Huang et al. 2009). Upon differentiation into
the CD342state, there is a remarkable down-regulation of
genes for other lineage specifications except for erythroid
d i f f e r e n t i a t i o n .T h i si sc o n s i stent with the fact that CD342
cells can no longer proliferate in SCF alone; they depend on an
additional cytokine, IL-3, for growth. Therefore, TCF7,
together with RUNX1, controls a transcriptional regulatory
network determining the choice between EML cell self-renewal
of multipotent cells and differentiation. The silencing of Tcf7 in
the CD342 cells would contribute to the commitment to
differentiation.
Discussion
In this study, we identified TCF7 as a regulator in the decision
of EML multipotential hematopoietic precursor cell self-renewal
and differentiation. We further identified RUNX1 as a partner
and effector of TCF7 function. TCF7 and RUNX1 bind to a
significantly overlapping set of target genes and likely function
coordinately in regulating target genes. In particular, TCF7 and
RUNX1 bind to and potentially regulate a network of transcrip-
tion factors which characterize the gene expression pattern of
CD34+ cells. We validated our hypothesis using functional tests.
Tcf7 is a member of the T-cell factor family of transcription
factors that are the downstream effectors of the Wnt signal
transduction pathways. Wnt signaling inhibits the degradation of
beta-catenin protein by preventing its phosphorylation by GSK3
beta. In the absence of phsophorylation of N-terminal serine and
threonine residues, beta-catenin accumulates and is translocated
into the nucleus where it associates with members of the TCF
family of transcription factors, and furnishes them with a
transcriptional activation domain [20]. Wnt signaling can act in
a context dependent manner to either activate or repress
transcription [41]. The TCF family of transcription factors can
also either activate or repress the transcription of genes responsive
to Wnt signaling [18].
Wnt signaling has been implicated in self-renewal of hemato-
poietic stem cells and the growth of hematopoietic precursors
[21,22,23,24] although mice with defects in the Wnt signaling
pathway continue to develop normal mature cells of the
hematopoietic system. Although Tcf7 knockout mice have only
been reported to show a defect in thymocyte development [42,43],
there are multiple TCF family members in vivo which can have
redundant function and compensate for the loss of Tcf7 alone in
the knock-out mouse model. In the EML system the expression
level of other TCF family members are low and none of them
displayed as remarkable differential gene expression as observed of
Tcf7. An analysis of the repopulating activity of the subpopulations
of cells in Tcf72/2 mouse bone marrow could be useful in the
future to understand TCF7’s roles in vivo; but such an analysis can
be complicated by the stimuli from multiple signaling pathways in
the bone marrow and the stem cell niche.
In addition to TCF7’s role in thymocyte development, T-
lineage specification and differentiation [42,43,44], the present
study shows TCF7 plays a role in the EML model of
hematopoietic precursor cell differentiation and function; and
has a role in gene activation as well as repression, A number of
components of the Wnt signaling pathway, such as Lrp5 and Bcl9,
were expressed at higher levels in CD34+ than CD342 cells.
However, the data presented here suggest that regulation by Wnt
molecules is not a significant factor in EML cell growth and
differentiation. RNA-Seq showed only low levels of the Wnt
receptors frizzled 2, 5 and 7, and, at most, traces of Wnt9a and
10a mRNA in the CD34+ cell population, as well as a lack of
mRNA for other known Wnt molecules in these cells. Even the
trace amounts of Wnt9a and 10a mRNA seen by RNA-Seq in
CD34+ cells could not be detected by RT-PCR. Wnt9a and 10a
Figure 2. Identification of transcription factor binding targets using ChIP–Sequencing. (A) Tcf7 is bound by both itself and by RUNX1
(AML1). Peaks indicate ChIP-Sequencing signal. Input genomic DNA serves as the negative control. The ‘‘binding sites’’ tracks (black vertical bars)
show the transcription factor binding loci determined using the PeakSeq program (normalized against genomic input DNA; q-value,0.001). Data are
visualized in Integrated Genome Browser (B) Identification of evolutionarily conserved RUNX1 binding sites at Tcf7 promoter region using
REGULATORY VISTA. The graph shows conserved and aligned AML1/RUNX1 transcription factor binding sites between mouse and human genomes
using a matrix similarity score of 1 (the most stringent). Two versions of the AML1 binding sites were found (AML1 and AML_Q6). The *ECRs:
Evolutionary Conserved Regions are indicated by deep red blocks. The degree of conservation (50%–100%) is indicated by the height of the peaks.
Coding region is sown by blue and UTR is shown by yellow. (C) Runx1 promoter is bound by both TCF7 and itself.
doi:10.1371/journal.pgen.1002565.g002
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PLoS Genetics | www.plosgenetics.org 7 March 2012 | Volume 8 | Issue 3 | e1002565Figure 3. Binding site analyses suggest RUNX1 functions coordinately with TCF7 in regulating target genes. (A) In the Venn diagram,
the blue circle represents TCF7 target genes and red circle represents RUNX1 target genes. 3915 target genes (72% of all RUNX1 targets and 49% of
all TCF7 target genes) are common to each other. The hypergeometric p-value of the intersection (compared to the entire UCSC known gene
collection 24901 genes) is 6.72294e-56. (B) The graph represents the distribution of the distance of the RUNX1 peak to the TCF7 peaks. (C) The
distribution of TCF7 binding motifs and RUNX1 motifs in binding regions of both factors are presented. Since TCF7 had two versions of the motifs,
non-duplicate union of occurrence of both motifs was indicated in the table. The sequence of one (version) of the motif logos is shown in the table.
doi:10.1371/journal.pgen.1002565.g003
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PLoS Genetics | www.plosgenetics.org 8 March 2012 | Volume 8 | Issue 3 | e1002565Figure 4. Correlation of transcription factor binding targets with RNA–Seq differential gene expression data by GSEA. (A). A
statistically significant enrichment of TCF7 targets was shown among up-regulated genes in CD34+ cells (Nominal p-value=0, FDR q-value=0.02).
Differential gene expression was ranked by fold change between Lin-CD34+ cells and Lin-CD342 cells (x-axis). The most up-regulated genes in
CD34+ cells are shown on the left side (red), while the most up-regulated genes in CD342 cells were shown on the right side (blue). Black bars
represent the positions of genes in the ranked list. Enrichment score (ES, Y-axis) reflects the degree to which TCF7 binding targets are
overrepresented at the extremes of the ranked gene expression list. When the distribution is at random, the enrichment score is zero. Enrichment of
TCF7 targets at the top of the ranked list results in a large positive deviation of the ES from zero. (B) A statistically significant enrichment of RUNX1
targets was shown among up-regulated genes in CD34+ cells (Nominal p-value=0, FDR q-value=0). Enrichment of RUNX1 targets at the top of the
ranked list results in a large positive deviation of the ES from zero.
doi:10.1371/journal.pgen.1002565.g004
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are grown in conditioned medium and it is possible that this
medium contributed some Wnt. However, EML cells also grow
well in standard medium in the presence of only purified SCF so
that Wnt in the conditioned media does not seem to be a necessary
factor for the growth of the cells. Finally, when a Tcf/Lef-GFP
reporter was introduced into the EML cells, there was no GFP
signal of Wnt induced activity in these cells, although the cells did
respond to LiCl or external WNT ligands. We conclude that
TCF7 may function in these cells by a pathway operative without
autocrine Wnt signaling.
The present study suggests that TCF7 plays a dual role in global
gene network by promoting the expression of large number of
genes characteristic of self-renewing CD34+ cells (Figure 5C),
while repressing genes activated in partially differentiated CD342
state (Figure 5D). The effects of Tcf7 knock-down is a result of a
combination of both direct effects of losing TCF7 binding and
secondary effects of removal of the short form of RUNX1 or other
TCF7 targets. RUNX1 plays multiple roles in early hematopoietic
development and, unlike TCF7 or Wnt, is necessary for
emergence of hematopoietic stem cells [45]. In sea-urchin embryos
RUNX1 expression is linked to Wnt activity [46]. In EML cells,
TCF7 and RUNX1 bind to one another’s promoter and thus may
regulate each other. The Runx1 gene encodes both short and long
isoforms, and these have antagonistic effects. The short isoforms
promote maintenance and proliferation of progenitor cells, but the
Figure 5. Tcf7 shRNA gene knockdown experiments provide functional evidence. (A) qRT-PCR validation of the effect of three Tcf7 shRNA
knockdown constructs. Tcf7 shRNA constructs were shown in the figure using the last two digits of their product numbers: TRCN0000012678,
TRCN0000012679, TRCN0000012680. (B) Western blot analysis in TCF7 knockdown cell lines shows TCF7 protein and the shorter isoforms of RUNX1
are absent. Scrambled shRNA serves as a negative control. The polyclonal RUNX1 antibody recognizes the three major isoforms of RUNX1 ranging
from ,25 kDa to ,50 Kda. The anti actin antibody indicates equal loading. Tcf7 shRNA knockdown reduces cell proliferation in SCF (scrambled
shRNA serves as a negative control). (C) The down-regulated genes in Tcf7 shRNA knockdown cells are significantly enriched among up-regulated
genes in CD34+ cells (Nominal p-value=0, FDR q-value=0). (D) The up-regulated genes in Tcf7 shRNA knockdown cells are significantly enriched
among up-regulated genes in CD342 cells (Nominal p-value=0, FDR q-value=0.01898734). See Figure 4 legend for GSEA plot details.
doi:10.1371/journal.pgen.1002565.g005
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repopulation [47]. Remarkably, knockdown of Tcf7, caused the
short isoforms of RUNX1 to disappear at the protein level,
without changing the expression of the long isoforms. Therefore,
TCF7, in addition to direct effects on the transcription of
individual genes, may prevent differentiation by regulating the
relative abundance of RUNX1 isoforms which have opposing
effects on differentiation.
There may be additional unknown factors besides TCF7 and
RUNX1 that are central for switching between the two cell types.
Examination of the TCF7 binding targets whose expression is
altered by Tcf7 inhibition showed that a STAT3 motif was one of
the most frequently detectable transcription factor binding motifs
(Figure S5). Interestingly STAT3 was one of the transcription
factors that are up-regulated in the CD34+ cells, suggesting that
increased STAT3 levels might augment TCF7 mediated tran-
scriptional changes in the CD34+ cells. Among other transcription
factors whose mRNA levels are higher in CD34+ than in CD342
cells, Bcl9 and Jun are known modulators of the TCF7-beta-
catenin transcriptional response. Interestingly, analysis of the
binding targets of SCL/TAL1 in a stem/progenitor cell line HPC-
7 indicates that they largely overlap with TCF7 binding genes (163
out of 243 SCL target genes are in common with TCF7 targets)
[48]. Scl/Tal1 is one of the TCF7 target genes; however, Tcf7 is
not among the SCL/TAL1 target genes. Therefore, SCL/TAL1
may be a downstream mediator of TCF7 activation. In another
context Bcl3 has been reported to be increased by SCF signaling
[49], which may also contribute to the increase in Bcl3 mRNA
levels seen in CD34+ as compared to CD342 cells. Overall, these
results suggest that a major part of the transcriptional switch
between CD34+ and CD342 cells is mediated by a small network
of transcriptional mediators, with TCF7 central to the network.
Finally, when Tcf7 level is knocked down by shRNA, although the
transcription levels of many genes changed as mentioned earlier in
this paper, CD34+ RNA is not reduced by the knockdown.
Therefore, there may be additional transcription regulatory factors
required for the switch and this is a topic of our future
investigation.
Many models of regulated stem cell differentiation, such as
sperm and egg production, skin regeneration, intestinal cell
regeneration, and neural differentiation, involve control of the
choice of differentiation versus precursor renewal that depends on
contact or signaling to the stem cell from different types of cells in
anatomically circumscribed niches. The EML system provides a
clear example of a mammalian precursor cell that has the intrinsic
ability to produce a quantitatively balanced ratio of renewing
versus differentiated progenies. We have found that TCF7 is a
regulator of the self-renewal and differentiation switch and further
Figure 6. TCF7, together with RUNX1, regulates a transcriptional regulatory network. The network involved in HSC establishment and
development (red nodes), cell growth control (blue nodes) and multipotency (orange nodes) was identified among up-regulated genes in CD34+
cells (.2 fold) and displayed by Ingenuity Pathway Analysis software (IPA). Gray lines are IPA annotated relations based on the literature. Pink lines
indicate TCF7 or RUNX1 binding to gene targets that were identified by our ChIP-Seq experiments. The shades of green color of the nodes in the
network indicate the level of up-regulation in CD34+ cells. Sox4, Mpo, Tal1 and Ppard were TCF7 binding targets that were added to the network
manually because of their obvious interesting function in hematopoiesis and self-renewal. All other nodes were from default IPA analysis. Direct
relations were indicated by solid line or arrows. Indirect relations were indicated by dotted line. Please see Ingenuity Pathway Analysis software (IPA
https://analysis.ingenuity.com/) Online Help section for detailed definitions.
doi:10.1371/journal.pgen.1002565.g006
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how this important process is regulated.
Materials and Methods
MACS separation of CD34+ and CD342 cells
Suspension cultures of EML cells were maintained in SCF
containing medium as previously described [13]. Total EML cells
were washed twice in FACS buffer (0.5% BSA, 1 mM EDTA, 16
PBS) and resuspended in 40 mlF A C Sb u f f e rp e r1 610
7 cells.
15 ml of Mouse Lineage Depletion Cocktail biotin conjugated
antibody (Miltenyi Biotec) was added to the cells for 20 minutes
at 4uC. The labeled cells were washed twice in FACS buffer and
resuspended in 80 ml FACS buffer. 20 ml of paramagnetic
microbeads conjugated to anti-biotin antibody (Miltenyi Biotec)
was added to the cells and incubated for 20 minutes at 4uC. The
labeled cells were washed twice and resuspended in 2 ml FACS
buffer per 1610
7 cells. The cells were separated twice in an
AutoMACS cell separator (Miltenyi Biotec) using the depletion
program (0.5 mls per minute). The lineage negative (Lin-)
fraction was resuspended in 100 ml (per 1610
7 cells) of FACS
buffer and CD34 biotin conjugated antibody was added (1 mgp e r
1610
6 cells). The labeled cells were washed in FACS buffer as
above and bound to anti-biotin coated beads. The cells were
separated in an AutoMACS cell separator (Miltenyi Biotec) using
a double positive separation program. The subsequent Lin-
CD342 fraction was resorted with the AutoMACS separator
using the depletion program. Lin-CD34+ and Lin-CD34+ cells
were collected. The cell purity was checked after each separation
using FACS and only cell purity .90% was used for further
experimentation.
FACS separation of CD34+ and CD342 cells
Total EML cells were washed twice in FACS buffer (0.5%
BSA, 1 mM EDTA, 16 PBS) and resuspended in 100 mlF A C S
buffer per 1610
6 cells. CD34-FITC (1 mgp e r1 610
6 cells;
Ebiosciences) was added to the cells and incubated for 1 hour at
4uC. Sca1-PE (0.06 mgp e r1 610
6 cells; Ebiosciences) and
Lineage Cocktail APC (5 mlp e r1 610
6 cells; Miltenyi Biotec)
were added to the cells and incubated for an additional
30 minutes. Lin-SCA+CD34+ and Lin-SCA-CD342 cells were
collected using FACS Aria (Beckman).
Illumina RNA–Sequencing and analysis
mRNA samples were prepared from 2610
6 CD34+ and
CD342 cells. RNA-Seq was performed as described [50]. Two
biological replicas and two technical replicas were used for each
cell type. The mouse genome sequence, annotation and genomic
features (genes, cDNAs, 39 UTRs, 59 UTRs, introns, exons,
intergenic regions, ESTs) for the mm9 database release were
directly downloaded from UCSC Table Browser (http://genome.
ucsc.edu) or obtained from Galaxy (http://galaxy.psu.edu/). Raw
Illumina reads were obtained after base calling in the Solexa
Pipeline version 0.2.2.6. RNA-Seq reads were mapped to the
mouse genome using Illumina’s ELAND software. Differentially
expressed gene features were identified using the ERANGE
package [51]. Read coverage along the annotated transcription
units was calculated using the ShortRead package [52].
Repetitive mapped reads were combined with uniquely mapped
reads to produce a final RPKM (reads per kilobase of mRNA, per
million total reads), using the procedure defined for ERANGE, by
calculating the probability that a multiread came from a particular
known or candidate exon based on the distribution of counts of
uniquely mapped reads in each exon. The resulting fractional
counts were added to the total count for the gene locus, which was
renormalized into a multi RPKM (Gene expression values:
Dataset S1).
Transcription factors were identified from the list provided by
Luscombe et al [53] of human transcription factors. Homologous
mouse genes were obtained for each from the Ensembl database
using the biomaRt package. We identified genes with different
expression levels in CD34+ versus CD342 cells as those with at
least a two fold difference in RPKM and in which both cell types
had a minimum of 2 RPKM.
ChIP–Sequencing
ChIP-Seq was performed as described [54,55,56]. 5610
7
formaldehyde cross-linked Lin-CD34+ and Lin-CD342 cells were
used. TCF7 goat polyclonal antibody TCF1(H18) (Santa Cruz
Biotechnology: catalog#SC8589), anti-AML(RUNX1) rabbit
polyclonal antibody [36] (CalBiochem: catalog#PC284), and
monoclonal RNA PolII antibody (Covance: catalog#8WG16-
MMS-126R) were used. IP-western experiments were done to
ensure the specificity of the antibodies.
ChIP–Seq data analysis
ChIP-Sequencing data were analyzed using the PeakSeq
program as previously described [57]. The transcription factor
binding loci were extracted with statistically significant signals (q-
value,0.001). Subsequently, we mapped the binding sites to
RefSeq genes in UCSC mm9 database (genome.ucsc.edu). A gene
was designated as the target gene if the peak was present within
3000 nt upstream of the transcription start site or inside of the gene
(including both exonic and intronic regions). ChIP-Seq data have
been deposited to GEO database (GSE31221; reviewer access link:
http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?token=lxglzumie
wawcha&acc=GSE31221.) In TCF7 and RUNX1 coregulation
analysis, known motifs for each of TCF7 and RUNX1 were
obtained from Jaspar and Transfac databases. We random selected
600 sequences bound inTCF7and RUNX1ChIP-Seqexperiments,
and performed denovo binding motifsearch. Wecompared these de
novo binding motifs with the known motifs (from Jaspar and
Transfac databases) of RUNX1 and TCF7.
Gene Ontology (GO) analysis, Gene Set Enrichment
Analysis (GSEA), and Ingenuity Pathway Analysis (IPA)
We used BiNGO [35] to determine the statistically over-
represented (p-value,0.0001) Gene Ontology (GO) categories
within the target gene sets of the transcription factors, and then
visualized the relationships of these GO categories with the
Cytoscape software [58].
We also performed Gene Set Enrichment Analysis (GSEA) [37]
to correlate transcription factor binding information with the gene
expression data. The expression dataset was rank-ordered by fold
change (difference of classes ranking metric) such that the most up-
regulated genes in Lin-CD34+ cells were on the top of the ranked
list, while the most up-regulated genes in Lin-CD342 cells (down-
regulated genes in Lin-CD34+ cells) were at the bottom of the
ranked list. GSEA analysis was used to determine whether
members of a binding target list, are randomly distributed
throughout the gene expression data or primarily enriched toward
the top or bottom of the gene expression list using the default
weighted enrichment statistic.
Ingenuity Pathway Analysis (IPA) was performed to display the
transcription factor regulatory networks (http://www.ingenuity.
com/).
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Fresh EML cells were recovered one week prior to shRNA
experiments in SCF containing growth medium (GM) as
previously described [13]. 1.5610
4 EML Lin-CD34+cells were
double FACS sorted and infected with shRNA constructs
containing Tcf7 (Sigma Aldrich) at an MOI=2 in a round bottom
96 well plate. Five shRNA constructs targeting different regions of
the Tcf7 gene were used (Sigma, shRNA product numbers:
TRCN0000012678, TRCN0000012679, TRCN0000012680,
TRCN0000012681, TRCN0000012682). SHC002VMISSION
Non-Target shRNA Control Transduction Particles (Sigma) were
used as shRNA negative control. To increase transduction
efficiency the ExpressMag systems (Sigma Aldrich) was used
according to manufacturer’s instructions. 24 hours post transduc-
tion, cells were selected in EML GM containing puromycin
(1.2 mg/ml). When indicated, selected cells were grown in
expansion medium (IMDB, 20% heat inactivated horse serum,
100 ng/ml SCF [PeproTech]). Cells were analyzed for knock-
down efficiency using qPCR (Tcf7 forward primer sequence
ATCCTTGATGCTGGGATTCTG; Tcf7 reverse primer se-
quence CTTCTCTTGCCTTGGGTTCTG. CD34 forward
primer sequence aggctgatgctggtgctagt; reverse primer sequence
ccccagctttctcaagtcag. Two internal controls: HPRT forward
primer tatgccgaggatttggaaaa; HPRT reverse primer acagagggcca-
caatgtgat, and/or beta Actin forward primer gatctggcaccacaccttct;
reverse primer accagaggcatacagggaca). In addition, Western blot
analysis was performed on puromycin-selected Tcf7 knockdown
cell lines to examine TCF7 and RUNX1 protein expression. The
polyclonal TCF7 antibody (Sigma Aldrich, catalog#AV34782)
and RUNX1 antibody (Abcam, catalog# ab23980) were used.
The anti actin (Abcam, catalog#ab8229) antibody was used to
indicate equal loading.
For Illumina array analysis, Lin- CD34+cells (1610
5) cells were
transduced at an MOI=1 with a Tcf7 targeting shRNA construct
TRCN0000012679 or a shRNA negative control. After a 24-hour
incubation with the shRNA-containing virus, the cells were grown
in EML GM for 24 hours, then cells were selected for 24 hours in
puromycin (1.2 mg/ml). Cells were harvested (a total of four days
after initial sort) and total RNA extracted. Total RNA from Tcf7
shRNA knockdown cells and control cells (transfected with
scrambled shRNA) was purified using the RNeasy Plus kit from
Qiagen. Hybridization to Illumina Mouse WG-6 v2.0 Expression
BeadChips was conducted at the Stanford Functional Genomics
Facility using standard Illumina protocols. The microarray data
was processed using the R version 2.11 Bioconductor Lumi
package. The gene expression values were offset so that all values
were made positive, subjected to the VST variance stabilization
transformation, and were then quantile normalized. Z scores are
plotted where Z=(x2m)/s, x is the log2 transformed gene
expression measurement and m and s are the mean and standard
deviations of expression of the gene. The microarray data is in
compliance with MIAME guidelines. The data have been
deposited in GEO database (GSE30068).
Monitoring endogenous Wnt signaling in EML cells
To test for the presence of wnt10a mRNA, four sets of PCR
primers were designed cross introns, which could distinguish
between genomic DNA and spliced cDNA.
Wnt10a forward primer 1:GCGCTCCTGTTCTTCCTACT,
Wnt10a reverse primer 1: GATCTGGATGCCCTGGATAG;
Wnt10a forward primer 2: GGCGCTCCTGTTCTTCCTAC,
Wnt10a reverse primer 2: ATGCCCTGGATAGCAGAGG;
Wnt10a forward primer 3: CATGAGTGCCAGCATCAGTT,
Wnt10a reverse primer 3: ACCGCAAGCCTTCAGTTTAC;
Wnt10a forward primer 4: CATGAGTGCCAGCATCAGTT,
Wnt10a reverse primer 4: AGCCTTCAGTTTACCCAGAGC.
Total EML cells (5610
4) were infected with lentivirus
containing either a CMV-GFP construct or a Tcf/Lef-GFP
construct (SABiosciences) at a MOI of 1, 5, 10, and 20. After
24 hours, cells were selected in EML GM with puromycin
(1.2 mg/ml). Selected cells were expanded in EML GM for 4–6
days. Cells were incubated for 24 hours in either LiCL (50 mM),
WNT3a (400 uM, PeproTech) or WNT5a (400 um, PeproTech).
Cells were analyzed by FACSCalibur (BD Biosciences).
Supporting Information
Figure S1 Analysis of the DNA sequence motifs that were
enriched among up-regulated genes in CD34+ cell. DIRE
analysis shows binding motifs of the TCF family of transcription
factors (TF) are among the DNA sequence motifs that were
enriched in up-regulated genes (.1.5 fold) in CD34+ cell. The
pie chart indicates the distribution of the locations of the potential
regulatory element. 1.5 kb upstream of the transcription start site
is considered as a promoter region. TF occurrence: percentage
of candidate regulatory elements containing a conserved bind-
ing site for a particular TF. TF importance: product of TF
occurrence and TF weigh (DiRE optimization procedure
calculates a weight for each transcription factor (TF) as a
measure of its association with the input gene set) (see details at:
http://dire.dcode.org/).
(TIF)
Figure S2 Minimum endogenous Wnt signaling in EML cells
detectable with a Tcf/Lef GFP reporter system. The Tcf/Lef
reporter is under the control of a minimum CMV promoter fused
in tandem to Tcf/Lef transcriptional response elements. A CMV-
GFP construct was used as a positive control (upper right panel).
The Tcf/Lef-GFP construct were used to infect total EML cells at a
MOI of 5 and 10 (the middle panels). In a parallel experiment, we
incubated EML cells infected with Tcf/Lef-GFP construct with
LiCl (50 mM) for 24 hours (lower panels). The percentage of cells
that show GFP signal is sown in the pink box.
(TIF)
Figure S3 Hierarchical relationships among enriched functional
categories of TCF7 binding targets via BiNGO. Gene Ontology
Analysis shows genes associated with regulation of transcription
were highly enriched in TCF7 targets. A P-value cutoff of 1.00E-4
was used to identify significantly enriched nodes. P-values are
indicated by a color scale as shown. Node size corresponds to the
number of genes within each category. Some category labels are
not shown for clarity.
(TIF)
Figure S4 De novo binding motifs overlap well with the known
motifs of RUNX1 or TCF7. (A). de novo binding motif derived
from TCF7 ChIP-Seq dataset (lower) showed statistically signif-
icant overlap (11 nt out of12 nt) with TCF7 known motif (upper)
in the same orientation. (B). de novo binding motif derived from
RUNX1 ChIP-Seq datasets (lower) showed statistically significant
overlap (10 out of 10 nt) with RUNX1 known motif (upper) in the
complementary orientation.
(TIF)
Figure S5 STAT3 motif enrichment. Examination of the genes
that are affected by Tcf7 inhibition showed that a STAT3 motif
was one of the most frequently detectable transcription factor
binding motifs among the genes that are also TCF7 binding
targets. (A). The top 10 enriched motifs identified among the up-
regulated TCF7 targets genes (.1.5 fold) when Tcf7 is knocked
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TCF7 targets genes (.1.5 fold) when Tcf7 is knocked down.
STAT3 is marked by a red circle in the list. See the legend of
Figure S1 for detailed description of DIRE analysis output.
(TIF)
Table S1 Enriched functional categories among differentially
expressed transcription factors in either CD34+ or CD342 cells.
IPA analysis: https://analysis.ingenuity.com/).
(TIF)
Table S2 Gene expression values of Wnt pathway components
in CD34+ and CD342 cells using RNA-Seq. Standard Deviation
was calculated among two biological replicas and two technical
replicas for each cell type.
(TIF)
Dataset S1 RNA–Seq gene expression values from each replica
of CD34+ and CD342 cells.
(XLS)
Dataset S2 TCF7 binding regions and other information
(scored by PeakSeq program, q-value,0.001).
(XLS)
Dataset S3 RUNX1 binding regions and other information
(scored by PeakSeq program, q-value,0.001).
(XLS)
Dataset S4 Target gene lists of TCF7 and RUNX1.
(XLS)
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